Tatva Chintan Pharma Chem Q2 FY27 Results: Consolidated Net Profit ₹21.45 Crore on Total Income of ₹219 Crore

Earnings
Specialty Chemicals

Blacklitt Research19 October 20262 min read

A technician in a white coat working at laboratory glassware, in an old black-and-white photograph — State Government Photographer, via Wikimedia Commons (CC0 1.0). Illustrative image.

Tatva Chintan Pharma Chem reported consolidated total income of ₹219.07 crore and net profit of ₹21.45 crore for the quarter ended 30 Sep 2026. Standalone total income was ₹210.19 crore and net profit was ₹15.39 crore.

Key highlights

Consolidated

Including its subsidiaries

Total income: ₹219 crore, up 75.9% YoY, up 29.0% QoQ
Net profit: ₹21.45 crore, up 116.2% YoY, up 34.2% QoQ
EPS: ₹9.17, against ₹4.24 in Q2 FY26
Finance costs: ₹2.71 crore, up from ₹0.51 crore a year earlier

Standalone

The company on its own, without its subsidiaries

Total income: ₹210 crore, up 80.2% YoY, up 39.4% QoQ
Net profit: ₹15.39 crore, up 72.1% YoY, up 47.3% QoQ
EPS: ₹6.57, against ₹3.82 in Q2 FY26
Revenue from operations: ₹207.48 crore, up 79.1% YoY and 41.4% QoQ

Summary

Consolidated ₹ crore
Particulars	Q2 FY27	Q2 FY26	YoY	Q1 FY27	QoQ
	219.07	124.52	+75.9%	169.84	+29.0%
Revenue from operations	217.32	123.51	+76.0%	167.06	+30.1%
Other income	1.75	1.01	+73.3%	2.78	-37.1%
	21.45	9.92	+116.2%	15.98	+34.2%
Finance costs	2.71	0.51	+431.4%	2.08	+30.3%
Depreciation	10.79	9.05	+19.2%	10.57	+2.1%
Tax expense	7.49	3.75	+99.7%	5.13	+46.0%
Net profit margin	9.79%	7.97%	+1.82 pp	9.41%	+0.38 pp
Tax as share of profit before tax	25.9%	27.5%	-1.57 pp	24.3%	+1.58 pp
EPS, basic (₹)	9.17	4.24	+116.3%	6.83	+34.3%

Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.

Revenue almost doubled and profit more than doubled, with a margin gain of under two points. Revenue from operations rose 76.0% to ₹217.32 crore and net profit 116.2% to ₹21.45 crore, a margin of 9.79% against 7.97%. Finance costs rose to ₹2.71 crore from ₹0.51 crore and depreciation 19.2% to ₹10.79 crore, both small against the revenue gain. Tax took 25.9% of profit before tax against 27.5%, and earnings per share were ₹9.17 against ₹4.24.

Against June revenue rose 30.1% and profit 34.2% from ₹15.98 crore. The filing text is only the covering note: the board approved the results on 19 October 2026 in a meeting from 11:30 AM to 3:45 PM, after the Audit Committee recommended them, and M/s. NDJ & Co. issued the limited review report. The results statement itself is not in the text read, so the figures here are the stored results for the quarter, and the filing gives no reason for the jump in revenue.

Standalone ₹ crore
Particulars	Q2 FY27	Q2 FY26	YoY	Q1 FY27	QoQ
	210.19	116.66	+80.2%	150.73	+39.4%
Revenue from operations	207.48	115.87	+79.1%	146.70	+41.4%
Other income	2.71	0.79	+243.0%	4.03	-32.8%
	15.39	8.94	+72.1%	10.45	+47.3%
Finance costs	2.71	0.51	+431.4%	2.08	+30.3%
Depreciation	10.79	9.05	+19.2%	10.57	+2.1%
Tax expense	5.05	3.40	+48.5%	3.65	+38.4%
Net profit margin	7.32%	7.66%	-0.34 pp	6.93%	+0.39 pp
Tax as share of profit before tax	24.7%	27.6%	-2.85 pp	25.9%	-1.20 pp
EPS, basic (₹)	6.57	3.82	+72.0%	4.47	+47.0%

Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.

The standalone company is most of the group. Standalone revenue from operations rose 79.1% to ₹207.48 crore, 95% of the group's, and net profit 72.1% to ₹15.39 crore, 72% of the group's ₹21.45 crore (derived), so subsidiaries contribute the other ₹6 crore. The standalone margin is 7.32%, lower than the group's 9.79%.

Inference

Tatva Chintan's revenue and profit both roughly doubled over a year, and the margin gain is modest.

The filing text read has no results statement or commentary, so the reason for the revenue growth and its repeatability are not known from it.

Reference: Original filing (PDF)

Sign up to continue reading

Create a free account to read the rest of this article and the analysis that follows.

Disclaimer:

The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.

Tatva Chintan Pharma Chem Q2 FY27 Results: Consolidated Net Profit ₹21.45 Crore on Total Income of ₹219 Crore

Key highlights

Consolidated

Standalone

Summary

Inference

Sign up to continue reading

Disclaimer:

Latest posts

Venus Pipes & Tubes Begins Commercial Production of Pipe Spooling on 20 October 2026

Crisil Reaffirms Uflex's AA-/Negative Rating on ₹4,600 Crore Bank Facilities

Moody's Affirms Yes Bank's Ba1 Deposit Rating With Stable Outlook After AT1 Ruling

Sterling and Wilson's South African Unit Sues Insurers Over ₹25.50 Crore Unpaid Bonds